Syncom Formulations (India) Limited SYNCOMF.BO Stock
Syncom Formulations (India) Limited Price Chart
Syncom Formulations (India) Limited SYNCOMF.BO Financial and Trading Overview
Syncom Formulations (India) Limited stock price | 12.25 INR |
Previous Close | 7.96 INR |
Open | 7.93 INR |
Bid | 8.01 INR x 0 |
Ask | 8.04 INR x 0 |
Day's Range | 7.88 - 8.17 INR |
52 Week Range | 4.55 - 11.65 INR |
Volume | 801.53K INR |
Avg. Volume | 754.51K INR |
Market Cap | 7.56B INR |
Beta (5Y Monthly) | 1.275342 |
PE Ratio (TTM) | 33.5 |
EPS (TTM) | 0.35 INR |
Forward Dividend & Yield | 0.03 (0.38%) |
Ex-Dividend Date | September 9, 2022 |
1y Target Est | N/A |
SYNCOMF.BO Valuation Measures
Enterprise Value | 6.87B INR |
Trailing P/E | 33.5 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 3.3701038 |
Price/Book (mrq) | 2.6613705 |
Enterprise Value/Revenue | 3.063 |
Enterprise Value/EBITDA | 35.135 |
Trading Information
Syncom Formulations (India) Limited Stock Price History
Beta (5Y Monthly) | 1.275342 |
52-Week Change | 13.22% |
S&P500 52-Week Change | 20.43% |
52 Week High | 11.65 INR |
52 Week Low | 4.55 INR |
50-Day Moving Average | 6.55 INR |
200-Day Moving Average | 7.53 INR |
SYNCOMF.BO Share Statistics
Avg. Volume (3 month) | 754.51K INR |
Avg. Daily Volume (10-Days) | 1.32M INR |
Shares Outstanding | 940M |
Float | 407.05M |
Short Ratio | N/A |
% Held by Insiders | 50.71% |
% Held by Institutions | 0% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.125 |
Last Split Factor | 35:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | March 31, 2023 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | March 31, 2024 |
Profitability
Profit Margin | 8.94% |
Operating Margin (ttm) | 6.72% |
Gross Margin | 36.81% |
EBITDA Margin | 8.71% |
Management Effectiveness
Return on Assets (ttm) | 2.74% |
Return on Equity (ttm) | 8.39% |
Income Statement
Revenue (ttm) | 2.24B INR |
Revenue Per Share (ttm) | 2.68 INR |
Quarterly Revenue Growth (yoy) | 4.70% |
Gross Profit (ttm) | 971.58M INR |
EBITDA | 195.47M INR |
Net Income Avi to Common (ttm) | 200.71M INR |
Diluted EPS (ttm) | 0.24 |
Quarterly Earnings Growth (yoy) | 78.10% |
Balance Sheet
Total Cash (mrq) | 708.97M INR |
Total Cash Per Share (mrq) | 0.84 INR |
Total Debt (mrq) | 831.81M INR |
Total Debt/Equity (mrq) | 32.49 INR |
Current Ratio (mrq) | 1.606 |
Book Value Per Share (mrq) | 3.021 |
Cash Flow Statement
Operating Cash Flow (ttm) | 105.29M INR |
Levered Free Cash Flow (ttm) | -119649752 INR |
Profile of Syncom Formulations (India) Limited
Country | India |
State | N/A |
City | Indore |
Address | 207, Saket Nagar |
ZIP | 452018 |
Phone | 91 73 1256 0458 |
Website | https://www.syncomformulations.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It offers various products, including generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agents, antiprotozoal, antivirals, bronchodilators, calcium antagonists, cardiac medicines, central nervous stimulants, cephelo sporins, cortico steroids, estrogen, cough suppressants, erectile dysfunction, and electrolite. The company also provides histamines, homeostatic, hypoglycemic, hypolipidaemics, local anesthetics, multivitamins and nutritional supplements, sedative anticonvulsants, stimulants, and sympathomimetic products, as well as products used in the treatment of gout. In addition, it engages in the trading of commodities and renting of properties. Further, the company exports its products. It offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquids orals, liquid vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and herbals. Syncom Formulations (India) Limited was founded in 1985 and is based in Indore, India.
Q&A For Syncom Formulations (India) Limited Stock
What is a current SYNCOMF.BO stock price?
Syncom Formulations (India) Limited SYNCOMF.BO stock price today per share is 12.25 INR.
How to purchase Syncom Formulations (India) Limited stock?
You can buy SYNCOMF.BO shares on the BSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Syncom Formulations (India) Limited?
The stock symbol or ticker of Syncom Formulations (India) Limited is SYNCOMF.BO.
Which industry does the Syncom Formulations (India) Limited company belong to?
The Syncom Formulations (India) Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does Syncom Formulations (India) Limited have in circulation?
The max supply of Syncom Formulations (India) Limited shares is 940M.
What is Syncom Formulations (India) Limited Price to Earnings Ratio (PE Ratio)?
Syncom Formulations (India) Limited PE Ratio is 35.00000000 now.
What was Syncom Formulations (India) Limited earnings per share over the trailing 12 months (TTM)?
Syncom Formulations (India) Limited EPS is 0.35 INR over the trailing 12 months.
Which sector does the Syncom Formulations (India) Limited company belong to?
The Syncom Formulations (India) Limited sector is Healthcare.